Resultados de procura - David V. Erbe
- Mostrando 1 - 8 Resultados de 8
-
1
-
2
An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria por Abigail Liebow, Xingsheng Li, Timothy Racie, Julia Hettinger, Brian R. Bettencourt, Nader Najafian, Patrick Haslett, Kevin Fitzgerald, Ross P. Holmes, David V. Erbe, William Querbes, John Knight
Publicado 2016Artigo -
3
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis por Simina Ticau, Gautham Sridharan, Shira Tsour, William Cantley, Amy Chan, Jason A. Gilbert, David V. Erbe, Emre Aldinc, Mary M. Reilly, David Adams, Michael Polydefkis, Kevin Fitzgerald, Akshay Vaishnaw, Paul Nioi
Publicado 2020Artigo -
4
A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia por Lacramioara Ivanciu, Raffaella Toso, Paris Margaritis, Giulia Pavani, Haein Kim, Alexander Schlachterman, Jianhua Liu, Valérie Clerin, Debra D. Pittman, Rosalind Rose-Miranda, Kathleen Shields, David V. Erbe, James F. Tobin, Valder R. Arruda, Rodney M. Camire
Publicado 2011Artigo -
5
Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface por Michael M. Schmidt, Sharon A. Townson, Amy Andreucci, Bracken M. King, Emily B. Schirmer, Alec Murillo, Christian Dombrowski, Alison W. Tisdale, Patricia Lowden, Allyson Masci, Joseph Kovalchin, David V. Erbe, K. Dane Wittrup, Eric S. Furfine, Thomas M. Barnes
Publicado 2013Artigo -
6
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1 por Yaacov Frishberg, Georges Deschênes, Jaap W. Groothoff, Sally‐Anne Hulton, Daniella Magen, Jérôme Harambat, William G. van’t Hoff, Ulrike Lorch, Dawn S. Milliner, John C. Lieske, Patrick Haslett, Pushkal Garg, Akshay Vaishnaw, Sandeep Talamudupula, Jiandong Lu, Bahru Habtemariam, David V. Erbe, Tracy L. McGregor, Pierre Cochat
Publicado 2021Artigo -
7
Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria por Tracy L. McGregor, Karen A. Hunt, Elaine Yee, Dan Mason, Paul Nioi, Simina Ticau, Marissa Pelosi, Perry R Loken, Sarah Finer, Debbie A. Lawlor, Eric B. Fauman, Qin Qin Huang, Chris Griffiths, Daniel G. MacArthur, Richard C. Trembath, Devin Oglesbee, John C. Lieske, David V. Erbe, John Wright, David A. van Heel
Publicado 2020Artigo -
8
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent por Dean R. Artis, Jack J. Lin, Chao Zhang, Weiru Wang, Upasana Mehra, Mylène Perreault, David V. Erbe, Heike I. Krupka, B.P. England, J. Malcolm O. Arnold, A.N. Plotnikov, Adhirai Marimuthu, Hoa Nguyen, Sarah Will, Maxime Signaevsky, John G. Kral, John Cantwell, Calvin Settachatgull, Douglas S. Yan, Daniel W. Fong, Angela J. Oh, Shenghua Shi, Patrick Womack, Benjamin E. Powell, Gaston Habets, Brian L. West, Kam Y. J. Zhang, Michael V. Milburn, George P. Vlasuk, K. Peter Hirth, K. B. Nolop, Gideon Bollag, Prabha N. Ibrahim, James F. Tobin
Publicado 2008Artigo
Ferramentas de procura:
Materias Relacionadas
Chemistry
Biochemistry
Biology
Internal medicine
Medicine
Endocrinology
Pharmacology
Enzyme
Kidney
Organic chemistry
Oxalate
Primary hyperoxaluria
Alternative medicine
Gastroenterology
Gene
Genetics
Immunology
In vivo
Pathology
Placebo
Receptor
Adipocyte
Adiponectin
Adipose tissue
Adverse effect
Agonist
Albumin
Amino acid
Amyloidosis
Antibody